Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SZM-1209 is an inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1).1 It selectively binds to RIPK1 over RIPK3 (Kds = 85 and >10,000 nM, respectively) and inhibits necrosome formation and phosphorylation of RIPK1 induced by TNF-α, SM-164 (Item No. 28632), and Z-VAD-FMK in HT-29 cells (EC50 = 22.4 nM). SMZ-1209 (10 and 20 mg/kg) decreases reductions in body temperature and improves survival in a mouse model of systemic inflammatory response syndrome (SIRS) induced by TNF-α and Z-VAD-FMK. It also reduces lung RIPK1 phosphorylation, IL-6 and TNF-α levels, and total protein content, as well as decreases the number of hemorrhagic sites and congestion edema, in a mouse model of acute lung injury (ALI) induced by short-term intratracheal exposure to 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK; Item No. 16414).
WARNING This product is not for human or veterinary use.
1. Targeting receptor-